Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Arsenic Trioxide (ATO) Clear all
Terminated Phase 1 Interventional

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

NCT00234000
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
arsenic trioxide, azacitidine
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 1 Interventional

Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma

NCT00720564
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Sep 28, 2026, 10:26 AM EDT
Not listed Phase 1Phase 2 Interventional

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

NCT00275067
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
arsenic trioxide, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

NCT02190695
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Interventions
Decitabine, Carboplatin, Arsenic trioxide
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

Study of Arsenic Trioxide in Small Cell Lung Cancer

NCT01470248
View directory record Official record
Conditions
Lung Cancer, Cancer of Lung, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Small Cell
Interventions
Arsenic Trioxide
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

NCT00866918
View directory record Official record
Conditions
Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
Interventions
Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis, Idarubicin, Mercaptopurine, Methotrexate, Mitoxantrone Hydrochloride, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 21 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
112
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 28, 2026, 10:26 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

NCT02339740
View directory record Official record
Conditions
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions
Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome

NCT00621023
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Decitabine, Arsenic Trioxide and Ascorbic Acid
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes

NCT00274781
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
arsenic trioxide, gemtuzumab ozogamicin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

NCT00201695
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Doxil®, Vincristine, Dexamethasone, Arsenic Trioxide
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis

NCT00572065
View directory record Official record
Conditions
Myelofibrosis
Interventions
arsenic trioxide, cytarabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 28, 2026, 10:26 AM EDT
Terminated Phase 1 Interventional

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT00590603
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Arsenic Trioxide, Ascorbic Acid and Bortezomib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 28, 2026, 10:26 AM EDT
Withdrawn Phase 1 Interventional

Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

NCT00504101
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
Arsenic trioxide, Bortezomib, Melphalan, Autologous hematopoietic stem cell transplantation
Drug · Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 28, 2026, 10:26 AM EDT
Not yet recruiting Phase 1 Interventional

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT07737769
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection, Bone Marrow Biopsy, Busulfan, Fludarabine
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

NCT00274820
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
ascorbic acid, arsenic trioxide, dexamethasone, thalidomide
Dietary Supplement · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

NCT00413166
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Idarubicin, Gemtuzumab Ozogamicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 28, 2026, 10:26 AM EDT
Terminated Phase 1 Interventional Results available

Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT03318016
View directory record Official record
Conditions
Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia
Interventions
Cyclophosphamide 500 MG, Cyclophosphamide 1000 MG, Cyclophosphamide 2000 MG, Cyclophosphamide 3000 MG, Cyclophosphamide 4000 MG
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 28, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia

NCT00184054
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Arsenic Trioxide (ATO), Ascorbic Acid
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 1 Interventional

Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment

NCT00449137
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Arsenic trioxide, Fluorouracil, Leucovorin calcium, Plasma levels of elemental arsenic, Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis, Tumor Biopsy (Fine-Needle Aspiration)
Drug · Other · Genetic + 1 more
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

NCT01404949
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
Tretinoin and Arsenic Trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Evanston, Illinois • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

NCT00469209
View directory record Official record
Conditions
Myeloma
Interventions
Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 28, 2026, 10:26 AM EDT
Completed Phase 1 Interventional

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT00258245
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
ascorbic acid, arsenic trioxide, bortezomib, dexamethasone, thalidomide, Aspirin
Dietary Supplement · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Sep 28, 2026, 10:26 AM EDT
Recruiting Phase 3 Interventional

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

NCT07504458
View directory record Official record
Conditions
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA, Acute Promyelocytic Leukemia
Interventions
QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA
Drug
Lead sponsor
Quetzal Therapeutics
Industry
Eligibility
18 Years to 71 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 28, 2026, 10:26 AM EDT
Suspended Phase 1 Interventional

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

NCT04996030
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
SY-2101, Arsenic Trioxide
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 28, 2026, 10:26 AM EDT